Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03358355 · ClinicalTrials.gov registry record · Phase 1
Unacylated Ghrelin to Improve FuncTioning in PAD: The GIFT Trial
A Phase 1 study, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT03358355: Completed Phase 1 study, sponsored by Northwestern University.
NCT03358355 is a Phase 1 study that has completed, run by Northwestern University. The registered enrollment target is 9 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03358355, a Phase 1 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
The GIFT pilot study will investigate the optimal subcutaneous dose and safety of subcutaneously administered unacylated ghrelin in older people with peripheral artery disease (PAD).
Primary Outcome
Levels of unacylated ghrelin are measured before and after every injection
Interventions
- DRUG unacelyated ghrelin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2016-06-07 |
| Est. Completion | 2017-08-30 |
| Phase | Phase 1 |
What the finished NCT03358355 record still lists
NCT03358355 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (85% lower).
The record links to 0 conditions, and to 1 intervention - of which unacelyated ghrelin is the first listed.
NCT03358355 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03358355 about?
NCT03358355 is a clinical study titled "Unacylated Ghrelin to Improve FuncTioning in PAD: The GIFT Trial". The GIFT pilot study will investigate the optimal subcutaneous dose and safety of subcutaneously administered unacylated ghrelin in older people with peripheral artery disease (PAD).
What is the current status of trial NCT03358355?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2016-06-07. Estimated completion is 2017-08-30.
What interventions are being tested in trial NCT03358355?
The interventions under investigation include: unacelyated ghrelin (DRUG).
Who is sponsoring clinical trial NCT03358355?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03358355's enrollment target sits among peer trials
9 1955th of 2000 higher than 42 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI